R
Ricard Cervera
Researcher at St Thomas' Hospital
Publications - 124
Citations - 4439
Ricard Cervera is an academic researcher from St Thomas' Hospital. The author has contributed to research in topics: Antiphospholipid syndrome & Lupus erythematosus. The author has an hindex of 33, co-authored 124 publications receiving 4015 citations.
Papers
More filters
Journal ArticleDOI
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
Laura Andreoli,George Bertsias,Nancy Agmon-Levin,S.J. Brown,Ricard Cervera,Nathalie Costedoat-Chalumeau,Andrea Doria,Rebecca Fischer-Betz,Frauke Förger,Maria Francisca Moraes-Fontes,Munther A. Khamashta,J. E. King,Andrea Lojacono,Francesca Marchiori,Pier Luigi Meroni,Marta Mosca,Mario Motta,Monika Østensen,Cristina Pamfil,Luigi Raio,Matthias Schneider,Elisabet Svenungsson,Maria G Tektonidou,Sule Yavuz,Dimitrios T. Boumpas,Angela Tincani +25 more
TL;DR: Recommendations for women's health issues in SLE and/or APS were developed using an evidence-based approach followed by expert consensus.
Journal ArticleDOI
Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus.
Munther A. Khamashta,Ricard Cervera,Ronald A. Asherson,Graham R. V. Hughes,D.J. Coltart,Josep Font,Miguel Ingelmo,C. Paré,Antonio Gil,J.J. Vázquez,José M. Oliver +10 more
TL;DR: Valvular heart disease, particularly affecting the mitral valve, is common in patients with SLE, and the presence of antibodies against phospholipids is associated with a higher prevalence of valvular abnormalities in these patients.
Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
Ricard Cervera,Ma. Khamashta,Y Shoenfeld,Mt Camps,S Jacobsen,E. Kiss,Mm Zeher,Angela Tincani,I. Kontopoulou Griva,Mauro Galeazzi,Francesca Bellisai,Pl Meroni,Rh Derksen,Pg Groot,E. Gromnica Ihle,Marta Baleva,Marta Mosca,Stefano Bombardieri,F. Houssiau,J-C Gris,Isabelle Quéré,E. Hachulla,Carlos Vasconcelos,B. Roch,A. Fernández Nebro,J-C Piette,Gerard Espinosa,Silvia Bucciarelli,Cn Pisoni,M L Bertolaccini,M C Boffa,G. R. V. Hughes +31 more
Abstract: Objectives: To identify the main causes of morbidity and mortality in patients with antiphospholipid syndrome (APS) during a 5-year period and to determine clinical and immunological parameters with prognostic significance. Methods: The clinical and immunological features of a cohort of 1000 patients with APS from 13 European countries who had been followed up from 1999 to 2004 were analysed. Results: 200 (20%) patients developed APS-related manifestations during the 5-year study period. Recurrent thrombotic events appeared in 166 (16.6%) patients and the most common were strokes (2.4% of the total cohort), transient ischaemic attacks (2.3%), deep vein thromboses (2.1%) and pulmonary embolism (2.1%). When the thrombotic events occurred, 90 patients were receiving oral anticoagulants and 49 were using aspirin. 31/420 (7.4%) patients receiving oral anticoagulants presented with haemorrhage. 3/121 (2.5%) women with only obstetric APS manifestations at the start of the study developed a new thrombotic event. A total of 77 women (9.4% of the female patients) had one or more pregnancies and 63 (81.8% of pregnant patients) had one or more live births. The most common fetal complications were early pregnancy loss (17.1% of pregnancies) and premature birth (35% of live births). 53 (5.3% of the total cohort) patients died. The most common causes of death were bacterial infection (21% of deaths), myocardial infarction (19%) and stroke (13%). No clinical or immunological predictor of thrombotic events, pregnancy morbidity or mortality was detected. Conclusion: Patients with APS still develop significant morbidity and mortality despite current treatment (oral anticoagulants or antiaggregants, or both).
Journal ArticleDOI
The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe.
TL;DR: The Euro-lupus project provides updated information on the epidemiologic characteristics of systemic lupus erythematosus at the change of the millennium and defines several clinical and immunological prognostic factors.
Journal ArticleDOI
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study.
Cecilia N. Pisoni,Antonio Brucato,A. Ruffatti,Gerard Espinosa,Ricard Cervera,M. Belmonte-Serrano,Julio Sánchez-Román,F. G. Garcia-Hernandez,Angela Tincani,Maria Tiziana Bertero,Andrea Doria,Grv Hughes,Munther A. Khamashta +12 more
TL;DR: IVIG at the dose and frequency used in this study was not effective as prophylactic therapy for CHB in high-risk mothers.